DAMORA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
DAMORA THERAPEUTICS, INC. (DMRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.72 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 587.40K shares, a 11554.76% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.14M shares, a 9019.41% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 434.51K shares, a 407.01% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 473.95K shares, a 426.49% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 90.02K shares, a 17.01% increase from fiscal 2023.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 76.93K shares, a 95.79% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.83M shares, a 12.06% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 587.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 3.72M shares 10-Q · filed 2026-08-10 | 4.16M shares derived: sum of 3 quarters · filed 2026-08-10 | 4.16M shares derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | 3.14M shares 10-Q · filed 2026-05-12 | 3.57M shares derived: sum of 2 quarters · filed 2026-05-12 | 3.57M shares derived: sum of 3 quarters · filed 2026-05-12 | 3.58M shares derived: sum of 4 quarters · filed 2026-05-12 | |
| 2025-12-31 | 434.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 434.51K shares derived: sum of 2 quarters · filed 2026-03-19 | 439.55K shares derived: sum of 3 quarters · filed 2026-03-19 | 473.95K shares 10-K · filed 2026-03-19 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 5.04K shares derived: sum of 2 quarters · filed 2025-11-06 | 39.44K shares 10-Q · filed 2025-11-06 | 125.14K shares derived: sum of 4 quarters · filed 2026-03-19 | |
| 2025-06-30 | 5.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 39.44K shares 10-Q · filed 2025-08-05 | 125.14K shares derived: sum of 3 quarters · filed 2026-03-19 | 21.46K shares derived: sum of 4 quarters · filed 2026-03-19 | |
| 2025-03-31 | 34.40K shares 10-Q · filed 2025-05-08 | 120.10K shares derived: sum of 2 quarters · filed 2026-03-19 | 16.42K shares derived: sum of 3 quarters · filed 2026-03-19 | 124.42K shares derived: sum of 4 quarters · filed 2026-03-19 | |
| 2024-12-31 | 85.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -17.98K shares derived: sum of 2 quarters · filed 2026-03-19 | 90.02K shares derived: sum of 3 quarters · filed 2026-03-19 | 90.02K shares 10-K · filed 2026-03-19 | |
| 2024-09-30 | -103.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | 4.32K shares derived: sum of 2 quarters · filed 2024-11-01 | 4.32K shares 10-Q · filed 2024-11-01 | -1.84M shares derived: sum of 4 quarters · filed 2025-03-19 | |
| 2024-06-30 | 108.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 108.00K shares 10-Q · filed 2024-08-12 | -1.74M shares derived: sum of 3 quarters · filed 2025-03-19 | -1.74M shares derived: sum of 4 quarters · filed 2025-03-19 | |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-04-29 | -1.85M shares derived: sum of 2 quarters · filed 2025-03-19 | -1.85M shares derived: sum of 3 quarters · filed 2025-03-19 | -1.72M shares derived: sum of 4 quarters · filed 2025-03-19 | |
| 2023-12-31 | -1.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -1.85M shares derived: sum of 2 quarters · filed 2025-03-19 | -1.72M shares derived: sum of 3 quarters · filed 2025-03-19 | 76.93K shares 10-K · filed 2025-03-19 | 1.92M shares 10-K · filed 2024-03-08 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 126.00K shares derived: sum of 2 quarters · filed 2023-11-06 | 1.92M shares 10-Q · filed 2023-11-06 | 1.92M shares derived: sum of 4 quarters · filed 2024-03-08 | |
| 2023-06-30 | 126.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | 1.92M shares 10-Q · filed 2023-07-31 | 1.92M shares derived: sum of 3 quarters · filed 2024-03-08 | 1.98M shares derived: sum of 4 quarters · filed 2024-03-08 | |
| 2023-03-31 | 1.80M shares 10-Q · filed 2023-04-28 | 1.80M shares derived: sum of 2 quarters · filed 2024-03-08 | 1.85M shares derived: sum of 3 quarters · filed 2024-03-08 | 1.98M shares derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 53.00K shares derived: sum of 2 quarters · filed 2024-03-08 | 179.00K shares derived: sum of 3 quarters · filed 2024-03-08 | 1.83M shares 10-K · filed 2024-03-08 | |
| 2022-09-30 | 53.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 179.00K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.83M shares 10-Q · filed 2022-11-08 | 1.90M shares derived: sum of 4 quarters · filed 2023-03-09 | |
| 2022-06-30 | 126.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | 1.77M shares 10-Q · filed 2022-07-29 | 1.85M shares derived: sum of 3 quarters · filed 2023-03-09 | 2.00M shares derived: sum of 4 quarters · filed 2023-03-09 | |
| 2022-03-31 | 1.65M shares 10-Q · filed 2022-04-29 | 1.72M shares derived: sum of 2 quarters · filed 2023-03-09 | 1.88M shares derived: sum of 3 quarters · filed 2023-03-09 | 2.34M shares derived: sum of 4 quarters · filed 2023-03-09 | |
| 2021-12-31 | 75.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 229.00K shares derived: sum of 2 quarters · filed 2023-03-09 | 695.00K shares derived: sum of 3 quarters · filed 2023-03-09 | 1.63M shares 10-K · filed 2023-03-09 | |
| 2021-09-30 | 154.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 620.00K shares derived: sum of 2 quarters · filed 2021-11-04 | 1.56M shares 10-Q · filed 2021-11-04 | 2.53M shares derived: sum of 4 quarters · filed 2022-02-17 | |
| 2021-06-30 | 466.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 1.40M shares 10-Q · filed 2021-08-05 | 2.38M shares derived: sum of 3 quarters · filed 2022-02-17 | ||
| 2021-03-31 | 936.00K shares 10-Q · filed 2021-05-04 | 1.91M shares derived: sum of 2 quarters · filed 2022-02-17 | |||
| 2020-12-31 | 977.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | 2.24M shares 10-K · filed 2022-02-17 | |||
| 2020-09-30 | 1.26M shares 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |